ReviewMagyar onkologia2026
[Changes in the surgery and histopathology of sentinel lymph nodes for breast cancer at the Bács-Kiskun County Teaching Hospital (Kecskemét) - Experiences of nearly 30 years and 4000 operations.]
Review in Magyar onkologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We introduced sentinel lymph node biopsy for breast cancer in 1997. Axillary lymphadenectomy was performed routinely at the beginning, then limited to sentinel node positive cases, macrometastatic cases and ultimately, to >2 nodes or post-neoadjuvant metastatic cases. From vital blue dye only labelling, (combined) radiocolloid, fluorescent and radar localisation labelling all received their place in the staging procedure. Histopathology also changed: 1. from extensive analysis identifying as many small metastases as possible to identifying/excluding macrometastatic involvement, 2. from routine to restricted use of immunohistochemistry, 3. from routine imprint cytology identifying as many macrometastases as possible to its selective use. The review describes these changes and also points to the rationale behind them. Along practical considerations, surgical and pathological techniques may undergo further changes in the future.
Indexed as
Identifiers
42731001PMC13577723What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.